Novo Nordisk's CagriSema Achieves 25% Weight Loss in Late-Stage Trial
New data shows Novo Nordisk's next-gen obesity drug CagriSema outperforms Wegovy, with women losing 25% of body weight in late-stage analysis.
Novo Nordisk is sharpening its competitive edge in the obesity drug race with fresh clinical evidence that its experimental injection CagriSema can deliver meaningfully greater weight loss than Wegovy, the company's current blockbuster GLP-1 therapy. The late-stage analysis found that women treated with CagriSema achieved approximately 25% weight loss — a figure that, if confirmed at scale, would set a new benchmark in pharmacological obesity treatment.
The result matters because Wegovy itself was considered a breakthrough when it launched, with clinical trials demonstrating roughly 15% average body weight reduction. A drug that significantly clears that bar could redefine patient expectations and prescribing standards across the field, at a moment when GLP-1 therapies are already reshaping how medicine approaches chronic weight management.
Read more LinkedIn Expert's One Networking Tip to Boost Your Reply Rate →
CagriSema is a combination of cagrilintide, an amylin receptor agonist, and semaglutide, the active ingredient in Wegovy. By targeting two separate metabolic pathways simultaneously, the drug appears designed to amplify the appetite-suppressing and weight-reducing effects beyond what a single-mechanism therapy can achieve. This dual-action approach reflects a broader industry push to stack complementary mechanisms rather than incrementally refine existing molecules.
For Novo Nordisk, the timing is strategically significant. The company faces intensifying competition from Eli Lilly's tirzepatide (Zepbound), which has also posted strong weight-loss numbers and gained market share. Demonstrating that CagriSema can outperform not just Wegovy but potentially rivals as well would reinforce Novo's position at the top of a market that analysts expect to be worth hundreds of billions of dollars globally within the next decade.
The late-stage nature of the analysis signals that CagriSema is advancing through the regulatory pipeline, though full approval timelines have not been specified in the available data. Investors and clinicians alike will be watching for broader trial results and eventual FDA submission details. Continue reading at US Top News and Analysis.
